An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients. The drug, VX-770, appeared to improve function of what is known as CFTR — the faulty protein responsible for CF. It is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis.